PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models

Journal of Nuclear Medicine

Volumn 52, Issue 12, 2011, Pages 2001-2008

  Oude Munnink, Thijs H ^a   Arjaans, Marlous E A ^a   Timmer Bosscha, Hetty ^a   Schrod̈er, Carolina P ^a   Hesselink, Jan W ^a   Vedelaar, Silke R ^a   Walenkamp, Annemiek M E ^a   Reiss, Michael ^b   Gregory, Richard C ^c   Lub de Hooge, Marjolijn N ^a   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

89Zr; Fresolimumab; Positron emission tomography; Transforming growth factor

Indexed keywords

CHELATING AGENT; FRESOLIMUMAB ZR 89; IMMUNOGLOBULIN G IN 111; N SUCCINYLDESFERRIOXAMINE B TETRAFLUOROPHENOL; RADIOISOTOPE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FRESOLIMUMAB; MONOCLONAL ANTIBODY; ZIRCONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL AGGREGATION; CHINESE HAMSTER; CONJUGATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; LIVER; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFICATION; QUALITY CONTROL; TISSUE HOMOGENATE; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; CHO CELL; CRICETULUS; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; IMMUNOLOGY; METABOLISM; METASTASIS; METHODOLOGY; PATHOLOGY; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTOPE LABELING; LIVER; MALE; MICE; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; ZIRCONIUM;

EID: 83755168244     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.092809     Document Type: Article

References (34)

1. Massagué J. TGFbeta in cancer. Cell. 2008;134:215-230.
2. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 1996;7:93-102. (Pubitemid 27202668)
3. Moutsopoulos NM, Wen J, Wahl SM. TGF-beta and tumors: an ill-fated alliance. Curr Opin Immunol. 2008;20:234-240.
4. Stover DG, Bierie B, Moses HL. A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem. 2007;101:851-861. (Pubitemid 47040867)
5. Reiss M, Barcellos-Hoff MH. Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat. 1997;45:81-95. (Pubitemid 27338535)
6. Khalil N. TGF-beta: from latent to active. Microbes Infect. 1999;1:1255-1263.
7. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci. 2003;116:217-224. (Pubitemid 36163863)
8. Wick W, Naumann U, Weller M. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr Pharm Des. 2006;12:341-349.
9. Korpal M, Kang Y. Targeting the transforming growth factor-beta signalling pathway in metastatic cancer. Eur J Cancer. 2010;46:1232-1240.
10. Garber K. Companies waver in efforts to target transforming growth factor beta in cancer. J Natl Cancer Inst. 2009;101:1664-1667.
11. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11:259-273. (Pubitemid 46349843)
12. Bierie B, Chung CH, Parker JS, et al. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest. 2009;119:1571-1582.
13. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009;11:1287-1296.
14. Serganova I, Moroz E, Vider J, et al. Multimodality imaging of TGFbeta signaling in breast cancer metastases. FASEB J. 2009;23:2662-2672.
15. Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009;15:960-966.
16. Morris JC, Shapiro GI, Tan AR, et al. Phase I/II study of GC1008: a human antitransforming growth factor-beta monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma [abstract]. J Clin Oncol 2008;26(suppl):9028.
17. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313-1319. (Pubitemid 47242797)
18. 89Zr- bevacizumab PET imaging in renal cell carcinoma patients: feasibility of tumor VEGF quantification [abstract]. Available at: http://poster-submission.com/ search/. Accessed November 3, 2011.
19. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest. 2005;115:44-55. (Pubitemid 40385504)
20. 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281.
21. Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 1990;50:4221-4226. (Pubitemid 20225655)
22. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
23. 89Zr-trastuzumab for HER2/neu ImmunoPET imaging. J Nucl Med. 2009;50:974-981.
24. Klass BR, Grobbelaar AO, Rolfe KF. Transforming growth factor beta1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance. Postgrad Med J. 2009;85:9-14.
25. Lin X, Duan X, Liang YY, et al. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell. 2006;125:915-928. (Pubitemid 43795197)
26. Coffey RJ Jr, Kost LJ, Lyons RM, Moses HL, LaRusso NF. Hepatic processing of transforming growth factor beta in the rat: uptake, metabolism, and biliary excretion. J Clin Invest. 1987;80:750-757. (Pubitemid 18003946)
27. Masuda H, Takakura Y, Hashida M. Pharmacokinetics and disposition characteristics of recombinant decorin after intravenous injection into mice. Biochim Biophys Acta. 1999;1426:420-428. (Pubitemid 29078557)
28. Hering S, Isken E, Knabbe C, et al. TGFb1 and TGFb2 mRNA and protein expression in human bone samples. Exp Clin Endocrinol Diabetes. 2001;109:217-226. (Pubitemid 32577689)
29. Hawinkels LJ, Verspaget HW, van Duijn W, et al. Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients. Br J Cancer. 2007;97:398-404. (Pubitemid 47196749)
30. Sheppard D. Integrin-mediated activation of latent transforming growth factor β. Cancer Metastasis Rev. 2005;24:395-402. (Pubitemid 41569979)
31. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest. 1990;86:1976-1984.
32. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136-151.
33. 89Zr- trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer. 2010;46:678-684.
34. 89Zr-trastuzumab and PET Imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.